Evidence map›Paper›PMID 41614569›Full record

ArticleEuropean journal of neurology2026

Serum sTREM2 Levels and Disability Progression in Patients With Primary Progressive Multiple Sclerosis.

Nicolás Fissolo, Pascal Benkert, Andreu Vilaseca-Jolonch, Yolanda Blanco, Harald Hegen, Klaus Berek, Francisco Pérez-Miralles, Konrad Rejdak, Luisa Villar, Enric Monreal and 17 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Nicolás FissoloServei de Neurologia, Centre D'esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall D'hebron (VHIR), Hospital Universitari Vall D'hebron. Universitat Autònoma de Barcelona, Barcelona, Spain.
Pascal BenkertDepartment of Biomedicine and Clinical Research, Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), University Hospital and University of Basel, Basel, Switzerland.
Andreu Vilaseca-JolonchServei de Neurologia, Centre D'esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall D'hebron (VHIR), Hospital Universitari Vall D'hebron. Universitat Autònoma de Barcelona, Barcelona, Spain.
Yolanda BlancoCenter of Neuroimmunology, Service of Neurology, Hospital Clinic, Institut D'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Harald HegenDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0002-2833-6337
Klaus BerekDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Francisco Pérez-MirallesNeuroimmunology Unit, València University and Polytechnic Hospital La Fe, València, Spain.
Konrad RejdakDepartment of Neurology, Medical University of Lublin, Lublin, Poland.
Luisa VillarDepartment of Neurology and Immunology, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigacion Sanitaria, Madrid, Spain.
Enric MonrealDepartment of Neurology, Hospital Universitario Ramón y Cajal, REEM, IRYCIS, Universidad de Alcalá, Madrid, Spain.
Roberto Alvarez-LafuenteEnvironmental Factors in Degenerative Diseases Research Group, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
Franziska BachhuberDepartment of Neurology, Ulm University, Ulm, Germany.
Hayrettin TumaniDepartment of Neurology, Ulm University, Ulm, Germany.
Sergio Martínez-YelamosDepartment of Neurology, Multiple Sclerosis Unit, Hospital Universitari de Bellvitge, Barcelona, Spain.
Antonio Sánchez-LópezNeuroimmunology Unit, Puerta de Hierro-Segovia de Arana Health Research Institute, Madrid, Spain.
Antonio García-MerinoNeuroimmunology Unit, Puerta de Hierro-Segovia de Arana Health Research Institute, Madrid, Spain.
Lucía GutiérrezServei de Neurologia, Centre D'esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall D'hebron (VHIR), Hospital Universitari Vall D'hebron. Universitat Autònoma de Barcelona, Barcelona, Spain.
Tamara Castillo-TriviñoNeurology Department, Hospital Universitario Donostia, San Sebastián, Spain.
Jan LyckeDepartment of Clinical Neuroscience, Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Igal RosensteinDepartment of Clinical Neuroscience, Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Nieves TéllezNeurology Department, Hospital Clínico Universitario de Valladolid., Valladolid, Spain.
Roberto FurlanDivision of Neuroscience, Clinical Neuroimmunology Unit, Institute of Experimental Neurology, IRCCS Ospedale San Raffaele, Milan, Italy.ORCID 0000-0001-7376-9425
Jan D LünemannDepartment of Neurology, University Hospital Münster, Münster, Germany.
Michael KhalilDepartment of Neurology, Medical University of Graz, Graz, Austria.
Jens KuhleDepartment of Biomedicine and Clinical Research, Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), University Hospital and University of Basel, Basel, Switzerland.
Xavier MontalbanServei de Neurologia, Centre D'esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall D'hebron (VHIR), Hospital Universitari Vall D'hebron. Universitat Autònoma de Barcelona, Barcelona, Spain.
Manuel ComabellaServei de Neurologia, Centre D'esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall D'hebron (VHIR), Hospital Universitari Vall D'hebron. Universitat Autònoma de Barcelona, Barcelona, Spain.

Funding

Agència de Gestió d'Ajuts Universitaris i de Recerca" (AGAUR; Generalitat de Catalunya) through Consolidated Research Groups 2021SGR00782
6 · The paper itself

Abstract

backgroundTriggering receptor expressed on myeloid cells 2 (TREM2) is a microglia surface receptor that aids in tissue repair and debris clearance. The soluble form, sTREM2, found in both blood and cerebrospinal fluid, is considered a biomarker for microglial activation. Based on the central role of microglia in MS pathogenesis, we aimed to investigate whether serum sTREM2 levels could predict disability progression in patients with primary progressive MS.

methodsSerum levels of sTREM2 were measured at baseline using a single-molecule array assay in a multicenter cohort of 137 primary progressive multiple sclerosis (PPMS) patients. Univariable and multivariable linear models evaluated the association between sTREM2 levels and EDSS change at 2 years, 6 years, and last follow-up.

resultsWhile an association was observed at 2 years only in non-inflammatory PPMS patients, no consistent relationship was found between sTREM2 levels and disability progression over longer follow-up.

conclusionsThese findings suggest that serum sTREM2 may have limited value as a biomarker of disability progression in PPMS.

Indexed as

Disease ProgressionMembrane GlycoproteinsMultiple Sclerosis, Chronic ProgressiveReceptors, ImmunologicAdultBiomarkersDisability EvaluationFemaleHumansMaleMiddle AgedBiomarkersMembrane GlycoproteinsReceptors, ImmunologicTREM2 protein, humanbiomarkersdisability progressionprimary progressive multiple sclerosissTREM2

Identifiers

PMID41614569
PMCPMC12856771

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.